Form 4 for AYTU AYTU BIOPHARMA, INC
Accepted 2024-10-02 00:00:00 ET · period of report 2024-09-30 · accession 0000912282-24-000682 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-10-02 | 2024-09-30 | AYTU | PYSZCZYMUKA GREG | Chief Commercial Off | M - OptEx | — | +209 | 23.2K | +0.9% | — |
| D | 2024-10-02 | 2024-09-30 | AYTU | PYSZCZYMUKA GREG | Chief Commercial Off | M - OptEx | $0.00 | -209 | 417 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2024-09-30 | M | A | 209 | — | 23,185 | D | — | — | (F1) Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025. |
| 2 | Derivative | Restricted Stock Units | 2024-09-30 | M | D | 209 | $0.00 | 417 | D | — · — to — | 209 Common Shares | (F1) Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025. |